Answers are grounded in this paper and cite their sources.
The capsule constitutes a pivotal virulence determinant in Streptococcus suis serotype 2 (SS2), conferring protection against host immune surveillance and phagocytic clearance. Given that sialic acid represents the predominant structural component of the SS2 capsule, this study devised an innovative screening methodology for capsule inhibitors, wherein sialic acid content was employed as a quantitative evaluation metric. Through this method, we have identified vanillin as a novel inhibitor capable of exerting potent suppression of SS2 capsule biosynthesis. Mechanistic investigations revealed that vanillin primarily suppresses the transcription of the capsule gene cluster, likely through downregulating luxS and ccpA . This suppression thus reduces capsule production, which in turn enhances bacterial adhesion to host cells and phagocytosis. In animal infection models, vanillin treatment significantly attenuated SS2 virulence and reduced bacterial loads in target organs. In summary, this study not only established a screening platform for SS2 capsule inhibitors but also successfully identified a promising candidate compound, offering a novel therapeutic strategy against SS2 infection.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: